Pennant Group (PNTG) Aktienübersicht
The Pennant Group, Inc. erbringt Dienstleistungen im Gesundheitswesen in den Vereinigten Staaten. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 2/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 0/6 |
PNTG Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
The Pennant Group, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$40.11 |
| 52-Wochen-Hoch | US$42.69 |
| 52-Wochen-Tief | US$22.26 |
| Beta | 1.27 |
| 1 Monat Veränderung | 2.01% |
| 3 Monate Veränderung | 18.39% |
| 1 Jahr Veränderung | 59.17% |
| 3 Jahre Veränderung | 261.03% |
| 5 Jahre Veränderung | 34.24% |
| Veränderung seit IPO | 165.81% |
Aktuelle Nachrichten und Updates
Narrative-Update • Sep 03
PNTG: Home Health Margin Momentum Will Drive Future Stock Upside
The Pennant Group analyst fair value estimate has been raised from $40.00 to $44.00, as analysts point to stronger Q2 results, higher full year guidance, improving home health and hospice margins, and a more stable reimbursement backdrop as key supports for the higher targets. Analyst Commentary on Pennant Group Recent Street research on Pennant Group centers on stronger Q2 performance, updated full year guidance and the outlook for margins in home health and hospice.
Narrative-Update • Aug 14
PNTG: Home Health And Hospice Expansion Plus AI Investments Are Expected To Support Upside
Pennant Group’s updated analyst price target has moved higher by about $2.83 to roughly $46.33, with analysts pointing to stronger Q2 performance, improving home health and hospice margins, and sector demand trends as key supports for the change. Analyst Commentary Recent research on Pennant Group focuses on how Q2 execution, margin trends, and sector demand expectations feed into updated valuation views.
Narrative-Update • Jul 30
PNTG: Sector Demand Tailwinds And Index Inclusion Will Support Future Upside
The Pennant Group analyst price target has moved from $40 to $49 as analysts point to updated assumptions on revenue growth, profit margins, and sector demand trends to support the higher valuation range. Analyst Commentary on Pennant Group Recent research updates on Pennant Group highlight a more constructive tone from bullish analysts who are revisiting their valuation work ahead of upcoming earnings.Recent updates
Narrative-Update • Sep 03
PNTG: Home Health Margin Momentum Will Drive Future Stock Upside
The Pennant Group analyst fair value estimate has been raised from $40.00 to $44.00, as analysts point to stronger Q2 results, higher full year guidance, improving home health and hospice margins, and a more stable reimbursement backdrop as key supports for the higher targets. Analyst Commentary on Pennant Group Recent Street research on Pennant Group centers on stronger Q2 performance, updated full year guidance and the outlook for margins in home health and hospice.Narrative-Update • Aug 14
PNTG: Home Health And Hospice Expansion Plus AI Investments Are Expected To Support Upside
Pennant Group’s updated analyst price target has moved higher by about $2.83 to roughly $46.33, with analysts pointing to stronger Q2 performance, improving home health and hospice margins, and sector demand trends as key supports for the change. Analyst Commentary Recent research on Pennant Group focuses on how Q2 execution, margin trends, and sector demand expectations feed into updated valuation views.Narrative-Update • Jul 30
PNTG: Sector Demand Tailwinds And Index Inclusion Will Support Future Upside
The Pennant Group analyst price target has moved from $40 to $49 as analysts point to updated assumptions on revenue growth, profit margins, and sector demand trends to support the higher valuation range. Analyst Commentary on Pennant Group Recent research updates on Pennant Group highlight a more constructive tone from bullish analysts who are revisiting their valuation work ahead of upcoming earnings.Narrative-Update • Jul 16
PNTG: Sector Tailwinds And Tech Investments Are Expected To Support Steady Upside
The analyst price target for Pennant Group has increased from $40.83 to $43.50. Analysts attribute this change to supportive sector trends in healthcare services, anticipated demand for care, and ongoing investments in growth and technology, which are key drivers behind their updated assumptions.Narrative-Update • Jul 02
PNTG: Q1 Senior Health Momentum And Expansion Are Expected To Support Upside
The Pennant Group analyst price target has increased by about $2.70 to roughly $40.83. Analysts attribute the change to updated views on fair value, profitability, and valuation multiples, following recent research from firms that raised their targets by $2, $3, and $6.Analyseartikel • Jun 21
Pennant Group (PNTG) Stock Could Be 12.4% Undervalued After Q1 Revenue Beat
Pennant Group (PNTG) is back in focus after reporting quarterly revenue growth of more than 35% year over year, alongside higher net profit, beating analyst expectations and drawing fresh attention to its decentralized operating model. See our latest analysis for Pennant Group. The recent Q1 surprise and focus on Pennant Group’s decentralized model come against a backdrop of building momentum, with a year to date share price return of 20.16% and a 3 year total shareholder return of 174.55%,...Narrative-Update • Jun 18
PNTG: Senior Health Momentum And Hartford Partnership Will Drive Future Stock Upside
Analysts have raised their price target on Pennant Group stock by a combined $11, citing updated views on the company supported by recent research from multiple firms. Analyst Commentary Recent research on Pennant Group stock points to a more nuanced view than the headline price target increases suggest.Narrative-Update • Jun 04
PNTG: Senior Living Expansion And Higher P/E Assumptions Will Support Future Upside Potential
Narrative Update on Pennant Group The analyst fair value estimate for Pennant Group has moved from $36.00 to $40.00, with analysts pointing to updated assumptions around revenue growth, profit margins, and a higher future P/E multiple as key drivers for the new price targets. Analyst Commentary Recent Street research around Pennant Group has centered on updated price targets that reflect revised assumptions for revenue, profitability, and the P/E multiple applied to future earnings.Narrative-Update • May 06
PNTG: AMED Asset Integration Will Drive Future Earnings Realization Potential
Analysts have raised Pennant Group's fair value estimate by $2 to $36, reflecting updated Street price targets and ongoing confidence that the company can gradually realize earnings potential from the AMED assets over time. Analyst Commentary Recent Street research has centered on how quickly Pennant Group can translate the AMED assets into consistent earnings and whether current valuation fairly reflects that path.Narrative-Update • Apr 22
PNTG: AMED Assets Are Expected To Underpin Future Upside Despite 2026 Guidance
Narrative Update Analysts have nudged Pennant Group's price target higher, with recent moves such as RBC Capital's increase to $41 from $39 contributing to a modest lift in estimated fair value and future P/E assumptions. Analyst Commentary Recent Street research around Pennant Group centers on how the market should weigh its guidance against longer term earnings potential from AMED assets and what that could imply for valuation.Narrative-Update • Apr 07
PNTG: AMED Assets Will Drive Future Upside Despite Softer 2026 Guidance
Narrative Update on Pennant Group Analysts have lifted Pennant Group's price targets into a $38 to $41 range, citing long-term earnings potential tied to AMED assets. They also hold a relatively favorable view of Medicare Advantage exposure, even with mixed near term guidance and sector headwinds.Narrative-Update • Mar 24
PNTG: AMED Assets Will Drive Future Upside Despite Softer 2026 Outlook
Narrative Update Analysts have recently nudged Pennant Group's average price target higher into the high $30s to low $40s range, citing confidence that the company can gradually realize earnings potential from the AMED assets, even though 2026 adjusted EBITDA guidance sits below earlier expectations. Analyst Commentary Recent research updates show analysts adjusting expectations for Pennant Group while still assigning higher price targets.Narrative-Update • Mar 10
PNTG: AMED Earnings Potential Will Offset Tempered Outlook For 2026
Pennant Group's updated fair value estimate edges up to about $37.83 from $37.50 as analysts lift price targets into the high $30s and low $40s, pointing to confidence in long term earnings potential from AMED assets, despite more tempered revenue growth assumptions and a slightly lower future P/E multiple. Analyst Commentary Recent research points to a generally constructive view on Pennant Group, with price targets shifting into the high $30s and low $40s range.Narrative-Update • Feb 24
PNTG: Fair Outlook Will Weigh Medicare Advantage Constructiveness Against Policy And Margin Risks
Analysts have raised their price target on Pennant Group from $31 to $38, with the higher fair value of $34 linked to updated views on revenue growth, profit margin, and a higher future P/E multiple in the context of a relatively constructive stance on Medicare Advantage. Analyst Commentary Even with the higher price target range and a constructive stance on Medicare Advantage, some commentary around Pennant Group points to risks that are worth keeping in mind as you weigh the setup.Narrative-Update • Feb 10
PNTG: Home Health Reimbursement Upside Will Drive Future Upside Optionality
Narrative Update on Pennant Group Analysts have raised their price target on Pennant Group to $38 from $31, citing potential upside from home health reimbursement rates even under conservative assumptions, and noting that recent regulatory concerns are already reflected in the shares. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside in the shares even when they assume conservative home health reimbursement rates, which they view as already reflected in the current valuation.Analyseartikel • Jan 28
With EPS Growth And More, Pennant Group (NASDAQ:PNTG) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Narrative-Update • Jan 26
PNTG: Home Health Reimbursement Upside Will Drive Future Upside Optionality
Analysts have lifted their price target on Pennant Group to US$38 from US$31, citing potential upside from home health reimbursement rates even under conservative assumptions. They also view the current valuation as offering attractive optionality if reimbursement trends improve.Narrative-Update • Jan 11
PNTG: Raised Fair Value Framework Will Rely On Home Health Reimbursement Outcomes
Analysts have raised their price target on Pennant Group from $31 to $38, citing updated fair value assumptions of $37.50, a higher future P/E estimate of 27.33, and expectations for stronger revenue growth, while also accounting for a slightly higher discount rate and a modestly lower profit margin outlook. Analyst Commentary Recent Street research provides a mix of optimism and caution around Pennant Group, with updated targets and ratings reflecting changing views on reimbursement, valuation, and sector risk.Narrative-Update • Dec 16
PNTG Will Balance Reimbursement Upside Against Policy And Margin Execution Risks
Pennant Group's analyst price target has been raised from $28 to $30 per share, as analysts highlight upside from potential home health reimbursement improvements despite conservative base case assumptions. Analyst Commentary While the latest target increase underscores growing optimism around home health reimbursement, not all market observers share an unequivocally bullish stance.Analyseartikel • Aug 09
The Pennant Group, Inc. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next
NasdaqGS:PNTG 1 Year Share Price vs Fair Value Explore Pennant Group's Fair Values from the Community and select yours...Analyseartikel • Jul 17
Earnings Tell The Story For The Pennant Group, Inc. (NASDAQ:PNTG)
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) price-to-earnings (or "P/E") ratio of 32.2x might make it look like a strong...Analyseartikel • Jun 28
Does Pennant Group (NASDAQ:PNTG) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • May 16
Pennant Group's (NASDAQ:PNTG) Earnings Are Weaker Than They Seem
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) stock was strong after they recently reported robust earnings. However, our...Analyseartikel • Apr 15
Is The Pennant Group, Inc. (NASDAQ:PNTG) Trading At A 33% Discount?
Key Insights Pennant Group's estimated fair value is US$38.66 based on 2 Stage Free Cash Flow to Equity Pennant Group...Analyseartikel • Mar 01
With EPS Growth And More, Pennant Group (NASDAQ:PNTG) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analyseartikel • Dec 21
Why Investors Shouldn't Be Surprised By The Pennant Group, Inc.'s (NASDAQ:PNTG) P/E
With a price-to-earnings (or "P/E") ratio of 44.5x The Pennant Group, Inc. ( NASDAQ:PNTG ) may be sending very bearish...Analyseartikel • Nov 14
Investors Shouldn't Be Too Comfortable With Pennant Group's (NASDAQ:PNTG) Earnings
Unsurprisingly, The Pennant Group, Inc.'s ( NASDAQ:PNTG ) stock price was strong on the back of its healthy earnings...Analyseartikel • Nov 12
Is The Pennant Group, Inc. (NASDAQ:PNTG) Trading At A 34% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Pennant Group fair value estimate is US$50.94 Current share...Analyseartikel • Oct 06
Is Now The Time To Put Pennant Group (NASDAQ:PNTG) On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Neues Narrative • Sep 16
Critical Acquisitions And Leadership Drive Remarkable Growth In Home Health Sector
Emphasis on expansion and acquisitions, such as the Muir Home Health joint venture, aims to significantly boost revenue and market share.Analyseartikel • Sep 14
Investors Still Waiting For A Pull Back In The Pennant Group, Inc. (NASDAQ:PNTG)
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) price-to-earnings (or "P/E") ratio of 53.9x might make it look like a strong...Analyseartikel • Aug 26
Does Pennant Group (NASDAQ:PNTG) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • May 14
Here's Why Pennant Group (NASDAQ:PNTG) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Aktionärsrenditen
| PNTG | US Healthcare | US Markt | |
|---|---|---|---|
| 7D | 5.6% | -0.4% | -1.5% |
| 1Y | 59.2% | 19.3% | 13.3% |
Rendite im Vergleich zur Industrie: PNTG übertraf die Branche US Healthcare , die im vergangenen Jahr eine Rendite von 17.3 erzielte.
Rendite vs. Markt: PNTG übertraf den Markt US, der im vergangenen Jahr eine Rendite von 13.9 erzielte.
Preisvolatilität
| PNTG volatility | |
|---|---|
| PNTG Average Weekly Movement | 4.1% |
| Healthcare Industry Average Movement | 7.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiler Aktienkurs: PNTG hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: PNTGDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2019 | 9,700 | Brent Guerisoli | pennantgroup.com |
The Pennant Group, Inc. bietet Gesundheitsdienstleistungen in den Vereinigten Staaten an. Das Unternehmen ist in zwei Segmenten tätig: häusliche Gesundheits- und Hospizdienste und Senior Living Services. Das Unternehmen bietet häusliche Gesundheitsdienste an, darunter klinische Dienste wie Krankenpflege, Sprach-, Ergo- und Physiotherapie, medizinische Sozialarbeit und häusliche Krankenpflegehelfer; und Hospizdienste, die klinische Pflege, Ausbildung und Beratungsdienste für die körperlichen, geistigen und psychosozialen Bedürfnisse von unheilbar kranken Patienten und ihren Familien umfassen.
The Pennant Group, Inc.'s Grundlagenzusammenfassung
| PNTG grundlegende Statistiken | |
|---|---|
| Marktanteil | US$1.37b |
| Gewinn(TTM) | US$32.32m |
| Umsatz(TTM) | US$1.10b |
43.3x
Kurs-Gewinn-Verhältnis 1.3x
Kurs-Umsatz-VerhältnisIst PNTG zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| PNTG Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$1.10b |
| Kosten der Einnahmen | US$885.88m |
| Bruttogewinn | US$215.83m |
| Sonstige Ausgaben | US$183.51m |
| Gewinn | US$32.32m |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 0.93 |
| Bruttomarge | 19.59% |
| Nettogewinnspanne | 2.93% |
| Schulden/Eigenkapital-Verhältnis | 48.8% |
Wie hat sich PNTG auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/14 02:59 |
| Aktienkurs zum Tagesende | 2026/09/14 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
The Pennant Group, Inc. wird von 8 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Brian Tanquilut | Jefferies LLC |
| Michael Wiederhorn | Oppenheimer & Co. Inc. |
| Benjamin Hendrix | RBC Capital Markets |